Coline Brossat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Coline Brossat has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Charles Khouri
Université Grenoble Alpes, INSERM U1300, HP2, and INSERM CIC1406, Grenoble, France (C.J.-B., C.K.).
3 shared publications - David Montani
INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
3 shared publications - Alex Hlavaty
University Grenoble Alpes, Pharmacovigilance Unit and Clinical Pharmacology Department (CIC-1406), Grenoble Alpes University Hospital, Grenoble, France (C.K., A.H.).
2 shared publications - Clément Jambon-Barbara
Université Grenoble Alpes, INSERM U1300, HP2, and INSERM CIC1406, Grenoble, France (C.J.-B., C.K.).
2 shared publications - Laurent Savale
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
2 shared publications - Marc Humbert
INSERM UMR_S 999, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Université Paris–Saclay , Le Kremlin Bicêtre
2 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Multimodal investigation of the association between bevacizumab and pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a rare and severe condition that may be associated with exposure to certain drugs. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been classified as having a possible association with PAH, but data remain scarce. This study aimed to assess the potential link between bevacizumab exposure and PAH through complementary clinical, medico-administrative and pharmacovigilance databases. Methods: We performed a multimodal investigation combining: (1) case identification from the French Pulmonary Hypertension (PH) Registry; (2) a population-based cohort analysis using the French National Health Data System (SNDS); and (3) a disproportionality analysis in the WHO pharmacovigilance database (VigiBase®). Clinical, hemodynamic, and exposure data were reviewed in the registry; prevalence of PAH in patients exposed to bevacizumab were computed in the SNDS; and disproportionality analyses (Information Component values) were calculated in VigiBase. Results: Seven cases of PAH temporally associated with bevacizumab were identified in the French PH registry, most displaying predisposing conditions (BMPR2 mutation, portal hypertension, or COPD). In the SNDS cohort of 9964 PAH patients, 30 had prior bevacizumab exposure, with no increased incidence compared to the general population. In VigiBase, 21 PAH cases were reported with bevacizumab, yielding a modest disproportionality signal only under broad definitions (IC=0.4 [0.1–0.6]). Discussion: Across complementary data sources, there was no evidence of a causal association between exposure to bevacizumab and the development of PAH in adults. However, the effect of bevacizumab as a secondary trigger in predisposed individuals cannot be definitely or completely excluded.
- 16 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (5)
Open AccessMultimodal investigation of the association between bevacizumab and pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a rare and severe condition that may be associated with exposure to certain drugs. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been classified as having a possible association with PAH, but data remain scarce. This study aimed to assess the potential link between bevacizumab exposure and PAH through complementary clinical, medico-administrative and pharmacovigilance databases. Methods: We performed a multimodal investigation combining: (1) case identification from the French Pulmonary Hypertension (PH) Registry; (2) a population-based cohort analysis using the French National Health Data System (SNDS); and (3) a disproportionality analysis in the WHO pharmacovigilance database (VigiBase®). Clinical, hemodynamic, and exposure data were reviewed in the registry; prevalence of PAH in patients exposed to bevacizumab were computed in the SNDS; and disproportionality analyses (Information Component values) were calculated in VigiBase. Results: Seven cases of PAH temporally associated with bevacizumab were identified in the French PH registry, most displaying predisposing conditions (BMPR2 mutation, portal hypertension, or COPD). In the SNDS cohort of 9964 PAH patients, 30 had prior bevacizumab exposure, with no increased incidence compared to the general population. In VigiBase, 21 PAH cases were reported with bevacizumab, yielding a modest disproportionality signal only under broad definitions (IC=0.4 [0.1–0.6]). Discussion: Across complementary data sources, there was no evidence of a causal association between exposure to bevacizumab and the development of PAH in adults. However, the effect of bevacizumab as a secondary trigger in predisposed individuals cannot be definitely or completely excluded.
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Breast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- 17 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (7) , 516-533
Open AccessBreast Cancer Reveals Latent BMPR2 -Related Susceptibility to Pulmonary Hypertension
BACKGROUND: Pulmonary arterial hypertension (PAH) and breast cancer disproportionately affect women. BMPR2 (bone morphogenetic protein receptor type 2) mutations, the most common genetic cause of heritable PAH, also exert tumor-suppressive functions, but their role in linking these diseases remains unclear. METHODS: We combined bioinformatic, epidemiologic, and experimental approaches. Public cancer datasets were mined for BMPR2 alterations. In vivo, mammary tumor development and pulmonary hemodynamics were assessed in female Bmpr2 +/Δ71 rats with or without carcinogen (7,12-dimethylbenz[a]anthracene) exposure. Pulmonary arterial smooth muscle cells were exposed to tumor-conditioned media to test inflammatory proliferation. Finally, associations between breast cancer and PAH were examined in the French National Healthcare Database (9964 patients with PAH). RESULTS: BMPR2 expression was markedly reduced in human breast tumors, with recurrent somatic variants and deep deletions identified. Bmpr2 +/Δ71 rats exhibited spontaneous mammary tumors and, following 7,12-dimethylbenz[a]anthracene exposure, developed exacerbated pulmonary hypertension with increased vascular remodeling and inflammation. Tumor-bearing Bmpr2 +/Δ71 rats showed elevated lung IL-1β and NF-κB activation. In vitro, conditioned media from Bmpr2 +/Δ71 tumors induced proliferation of Bmpr2 +/Δ71 pulmonary arterial smooth muscle cells via IL-1β–dependent signaling, while neutralization of IL-1β attenuated this effect. Human pulmonary arterial smooth muscle cells carrying BMPR2 mutations similarly displayed heightened IL-1β–induced proliferation. Epidemiologically, breast cancer incidence was more than doubled in patients with PAH compared with the general population, and PAH incidence was increased nearly 9-fold among patients with breast cancer, indicating a bidirectional relationship. CONCLUSIONS: These findings identify a reciprocal association between breast cancer and PAH mediated by defective BMPR2 signaling and tumor-associated inflammation. Breast cancer may act as a “second hit,” unmasking BMPR2 -related susceptibility to PAH, underscoring BMPR2 as a shared molecular vulnerability with implications for surveillance of at-risk populations.
- Open Access
- 16 February 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS
Extract Fenfluramine is an amphetamine derivative first available in in France and the US as an appetite suppressant in 1963 and 1973, respectively. Fenfluramine is a chiral molecule and has been marketed as a racemate (Pondimin) or a d-enantiomer, dexfenfluramine (Isomeride, Redux). Fenfluramine and its active metabolite, norfenfluramine, are 5-HT1B, 5-HT2C and 5-HT2B receptor agonists, increasing serotonergic transmission. Cardiovascular toxicity of fenfluramine is thought to result from excessive serotonergic stimulation, notably through activation of 5-HT2B receptors [1]. Shareable abstract The plausibility of pulmonary hypertension onset in patients exposed to fenfluramine, used in epilepsy, reinforces the importance of careful echocardiographic monitoring https://bit.ly/48XhPbr
- 16 February 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessFenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS
Extract Fenfluramine is an amphetamine derivative first available in in France and the US as an appetite suppressant in 1963 and 1973, respectively. Fenfluramine is a chiral molecule and has been marketed as a racemate (Pondimin) or a d-enantiomer, dexfenfluramine (Isomeride, Redux). Fenfluramine and its active metabolite, norfenfluramine, are 5-HT1B, 5-HT2C and 5-HT2B receptor agonists, increasing serotonergic transmission. Cardiovascular toxicity of fenfluramine is thought to result from excessive serotonergic stimulation, notably through activation of 5-HT2B receptors [1]. Shareable abstract The plausibility of pulmonary hypertension onset in patients exposed to fenfluramine, used in epilepsy, reinforces the importance of careful echocardiographic monitoring https://bit.ly/48XhPbr